News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CN NMPA Seeks Opinions on Inclusion in 30-Day Channel for Innovative Drug Clinical Trial Review & Approval Applications
China's National Medical Products Administration (NMPA) is publicly seeking opinions on the Announcement on Matters Related to the Optimization of Innovative Drug Clinical Tria...
Reset
Send
The window will close in 5 seconds
CN NMPA Seeks Opinions on Inclusion in 30-Day Channel for Innovative Drug Clinical Trial Review & Approval Applications
Close
Recommend
48
Positive
81
Negative
33
 
SHORT SELL
 
STOCK INFO

China's National Medical Products Administration (NMPA) is publicly seeking opinions on the Announcement on Matters Related to the Optimization of Innovative Drug Clinical Trial Review and Approval (Draft for Comments).

The announcement proposes that applications for inclusion in the 30-day channel for innovative drug clinical trial review and approval should be for Category 1 innovative drugs (traditional Chinese medicine, chemical drugs, and biological products). Their application materials also have to be submitted as required and meet a range of conditions. For instance, the drugs should be key innovative drugs with national support.

Related NewsCMBI Raises WUXI BIO (02269.HK) TP to $35.6; Rating Buy

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.